Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. You must be at least 18 years old~2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)~3. You must have had no prior systemic anticancer therapy for lung cancer~4. You must live close enough to the study doctor to be able to visit regularly for follow up~5. You must have signed informed consent form indicating your willingness to take part in this study~6. Your laboratory and medical history and tests must meet study requirements~Exclusion criteria:~1. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment~3. Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)~4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence~5. Brain metastasis~6. Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry~7. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry~8. Concurrent administration of any other antitumor therapy~9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)~10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation~11. Pregnancy or breast-feeding~12. You are allergic to pemetrexed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Pemetrexed + Best Supportive Care (Type: EXPERIMENTAL): Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
- B: Best Supportive Care (Type: ACTIVE_COMPARATOR): Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).